title: Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study.
abstract: BACKGROUND
  Few studies have investigated measures to prevent small bowel injuries induced by aspirin. Our aim was to evaluate the effect of probiotic treatment on the small bowel injuries induced by chronic low-dose aspirin use.
  
  
  METHODS
  Thirty-five patients who took low-dose enteric-coated aspirin 100 mg daily (for more than 3 months) plus omeprazole 20 mg daily and were diagnosed as having unexplained iron deficiency anemia participated in this prospective randomized controlled trial. We assigned the patients to receive probiotic treatment with Lactobacillus casei for 3 months (L. casei group) or not receive the probiotic (control group). Patients underwent capsule endoscopy (CE) before and after treatment.
  
  
  RESULTS
  Twenty-five patients, including 13 in the L. casei group and 12 in the control group, underwent the full analysis. Significant decreases in the number of mucosal breaks and the CE score were observed at the 3-month evaluation in the L. casei group as compared with the results in the control group (P = 0.039). The change from the baseline in the median number of mucosal breaks in the L. casei group was -2, as compared with 0.5 in the control group. The change from the baseline in the median CE score in the L. casei group was -228 compared with -4 in the control group (P = 0.026).
  
  
  CONCLUSIONS
  Co-administration of L. casei is effective for the treatment of aspirin-associated small bowel injury.
authors.affiliation: Division of Gastroenterology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. endo1978@yokohama-cu.ac.jp
authors.forename: Hiroki
authors.initials: H
authors.lastname: Endo
authors.forename: Takuma
authors.initials: T
authors.lastname: Higurashi
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Hosono
authors.forename: Eiji
authors.initials: E
authors.lastname: Sakai
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Sekino
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Iida
authors.forename: Yasunari
authors.initials: Y
authors.lastname: Sakamoto
authors.forename: Tomoko
authors.initials: T
authors.lastname: Koide
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Takahashi
authors.forename: Masato
authors.initials: M
authors.lastname: Yoneda
authors.forename: Chikako
authors.initials: C
authors.lastname: Tokoro
authors.forename: Masahiko
authors.initials: M
authors.lastname: Inamori
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Abe
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakajima
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018798:Anemia, Iron-Deficiency / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D053704:Capsule Endoscopy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007410:Intestinal Diseases / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D007413:Intestinal Mucosa / Q000187:drug effects; D007421:Intestine, Small / Q000187:drug effects*; D007780:Lacticaseibacillus casei; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage; D010865:Pilot Projects; D019936:Probiotics / Q000627:therapeutic use*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D009853:Omeprazole; D001241:Aspirin